Related Experiment Videos
Delayed neurotoxicity of intraventricular interleukin-2: a case report
1Department of Neuro-Oncology, University of Texas, Anderson Cancer Center, Houston.
Abstract:
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction. This deterioration started 3 months post-treatment and worsened over the ensuing 4 years. MRI revealed white matter abnormalities that were not present on the pretreatment scan. Although free of disease, the patient has a subcortical dementia and is unable to work. The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed.
Insights
Intraventricular interleukin-2 (IL-2) therapy for leptomeningeal disease can cause progressive cognitive dysfunction and white matter abnormalities. This case highlights potential long-term brain injury and disability risks associated with this treatment.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Neurology
Background:
- Leptomeningeal disease is a serious complication of various cancers.
- Intraventricular interleukin-2 (IL-2) has been used as a treatment for leptomeningeal disease.
- The potential neurotoxicity of intraventricular IL-2 is not fully understood.